ADA 2021: Tirzepatide Beats Semaglutide for Reduction of HbA1c and Weight in Type 2 Diabetes
The investigational agent is being compared in several treatment settings for type 2 diabetes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.